

14:00~15:20

## Poster Session ( I )

- P-001 Pituitary tumors in SDH mutation carriers**  
**Giuseppe Opocher**  
 - Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, Padova, Italy  
 - Department of Medicine, DIMED, University of Padova, Padova, Italy
- P-002 The Dr. Pheo Blog: virtual counseling on pheochromocytoma**  
**Run Yu**  
 Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America
- P-003 HIF2A mutations identified in a new syndrome of multiple paragangliomas, somatostatinomas and polycythemia**  
**Zhengping Zhuang**  
 NINDS, SNB, National Institutes of Health, Bethesda, United States of America
- P-004 Molecular mechanisms of hypersecretion in pheochromocytoma and its impact in tumor development**  
**Pauline Croisé**  
 Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212, Strasbourg University, Strasbourg, France
- P-005 The increased bone turnover in patients with pheochromocytoma**  
**Nao Hasuzawa**  
 Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Higashiku, Fukuoka, Japan
- P-006 Involvement of Max in expression of the genes regulating differentiation and tumorigenesis**  
**Mariko Sue**  
 - Department of Medicine III, Technische Universität Dresden, Dresden, Germany  
 - Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Germany
- P-007 Structural modeling predicts effect of Succinate Dehydrogenase subunit B mutations on mitochondrial localisation**  
**Edward Kim**  
 Cancer Genetics Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia
- P-008 Finding the 11p15 tumor suppressor gene in paraganglioma**  
**Attje Hoekstra**  
 Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands
- P-009 Succinate dehydrogenase subunit D (SDHD) and subunit B (SDHB) mutation in canine pheochromocytoma /paraganglioma**  
**Diana (Dindy) E Benn**  
 Cancer Genetics, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia
- P-010 Pathophysiologic Considerations in Patients with Pheochromocytoma without Hypertension**  
**Emmanuel L Bravo**  
 Nephrology & Hypertension, Cleveland Clinic, Cleveland, OH, United States of America

- P-011 Patient characteristics and molecular pattern of PCC and PGG harboring somatic H-RAS mutations**  
**Rajani Maharjan**  
*Department of Surgical Sciences, Uppsala University, Uppsala, Sweden*
- P-012 Somatic mutations, copy number and associated gene expression patterns in sporadic pheochromocytomas**  
**Jenny Welander**  
*Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden*
- P-013 Integrative Genomics Reveal Evolutionary Patterns and Clonal Heterogeneity in Pheochromocytoma Tumours**  
**Joakim Crona**  
*Department of Surgical Sciences, Uppsala University, Uppsala, Sweden*
- P-014 Extra- and intracellular succinate concentration under normoxic and hypoxic conditions**  
**Takahiro Mikami**  
*Department of Metabology, JSPS Research Fellowship, Graduate School of Medicine, Tokyo University, Tokyo, Japan*
- P-015 A novel animal model of phaeochromocytoma for preclinical therapy evaluation**  
**Christian G. Ziegler**  
*Department of Medicine, TU Dresden, Dresden/Saxonia, Germany*
- P-016 Tissue culture of tumor tissue from head and neck paragangliomas**  
**Jean-Pierre Bayley**  
*Human Genetics, Leiden University Medical Center, Haarlem, Netherlands*
- P-017 Characterization of a mouse pheochromocytoma cell line transfected with the firefly luciferase reporter gene**  
**Daniel A Pryma**  
*Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA, United States of America*
- P-018 SDH deficiency and PHEO/PGL development: the role of microenvironment in tumor progression**  
**Massimo Mannelli**  
*Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy*
- P-019 Catecholamine Biochemical Phenotype Correlations Clinical Characteristics of Pheochromocytoma /Paraganglioma**  
**Akiyo Tanabe**  
*Department of Medicine II, Tokyo Women's Medical University, Tokyo, Japan*
- P-020 Monitoring of hemodynamic parameters in pheochromocytoma patients using the Non-Invasive Cardiac system (NICaS)**  
**Yayoi Matsuda**  
*- Graduate School of Medicine, Saga University, Saga, Japan  
 - Graduate School of Medicine, Kyushu University, Japan*
- P-021 Change in insulin sensitivity and insulin secretion in patients with pheochromocytoma before and after adrenalectomy**  
**Shinsuke Tokumoto**  
*Center for Diabetes & Endocrinology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan*

- P-022** Clinical and other characteristic features of pediatric vs adult pheochromocytomas/paragangliomas  
**YITA** Christina Pamporaki  
 Department of Medicine III, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
- P-023** Evaluation of <sup>18</sup>F-FDG kinetics in pheochromocytoma and paraganglioma by dynamic PET/CT scanning  
 Anouk van Berkel  
 Department of Endocrinology / Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
- P-024** Use of semi-quantitative <sup>123</sup>I-MIBG to distinguish pheochromocytoma from physiological adrenal uptake  
 Anouk van Berkel  
 Department of Endocrinology / Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
- P-025** Characterization of transporter expression in pheochromocytomas a correlation with MIBG scintigraphy and FDG-PET  
 Ikki Sakuma  
 Graduate School of Medicine, Chiba University, Chiba, Japan
- P-026** In vitro analysis of SDHx sequence variants suspected to affect splicing using a minigene assay  
 Francesca Schiavi  
 Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IRCCS, Padova, Italy
- P-027** Germline Mutation in the SDHB in Japanese Malignant Pheochromocytomas  
 Kazuhiro Takekoshi  
 Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
- P-028** The miRNA 483-5p, miRNA 183, miRNA 21 and miRNA 210 expressions in pheochromocytoma and paraganglioma  
 Qi Sun  
 Endocrinology, Peking Union Medical College Hospital, Beijing, China
- P-029** Germline and somatic genetic study of 535 Spanish pheochromocytoma and paraganglioma's patients  
 Maria Curras  
 Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain
- P-030** The TCA Cycle Gene Mutation Database - the First Decade  
 Jean-Pierre Bayley  
 Human Genetics, Leiden University Medical Center, Haarlem, Netherlands
- P-031** Multi-gene panel detects pheochromocytoma/paraganglioma individuals with multiple germline mutations  
 Trish Dwight  
 - Cancer Genetics Group, Kolling Institute of Medical Research, St Leonards, Australia  
 - Faculty of Medicine, University of Sydney, Sydney, Australia  
 - Endocrinology, Royal North Shore Hospital, Australia
- P-032** Genetic Study of Thai Patients with Pheochromocytoma/Paraganglioma  
 Thiti Snabboon  
 Medicine, Chulalongkorn University, Bangkok, Thailand
- P-033** Surgery and germline mutations of cervical paragangliomas  
 Kiyoto Shiga  
 Department of Otolaryngology-Head & Neck Surgery, Iwate Medical University, Morioka, Iwate, Japan

- P-034** Safety of laparoscopic surgery for pheochromocytoma patients that developed catecholamine cardiomyopathy  
**Dai Takeuchi**  
*Breast and Endocrine Surgery, Nagoya University, Nagoya, Aichi, Japan*
- P-035** Surgical treatment of 10 cases of cardiac paragangliomas: The PUMC hospital experience  
**Qi Miao**  
*Cardiac Surgery, Peking Union Medical College Hospital, Beijing, China*
- P-036** Laparoscopic adrenalectomy for pheochromocytoma: Surgical and clinical outcomes with long-term follow-up  
**Takashi Kasahara**  
*Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan*
- P-037** Excision of phaeochromocytomas and paragangliomas involving the great vessels  
**Umasuthan Srirangalingam**  
*Endocrinology, St Bartholomew's Hospital, Kent, United Kingdom*
- P-038** Knack of laparoscopic partial adrenalectomy for bilateral pheochromocytoma in multiple endocrine neoplasia type2  
**Tadasuke Ando**  
*Department of Urology, Faculty of Medicine, Oita University, Yufu, Oita, Japan*
- P-039** Adrenalectomy in elderly with pheochromocytoma/paraganglioma: a comparative analysis with young adult patients  
**Victor Srougi**  
*University of Sao Paulo, Sao Paulo, Brazil*
- P-040** Acute leukemia therapy elicits impressive response in chemoradioresistant metastatic paraganglioma: case report  
**Shakeel Modak**  
*Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America*
- P-041** Heterogeneous tumor response to CVD chemotherapy in the metastatic lesions of malignant pheochromocytoma  
**Mika Tsuiki**  
*Dept. Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan*
- P-042** I-131 metaiodobenzylguanidine therapy for malignant pheochromocytoma; a case of the largest dose in Japan  
**Anri Inaki**  
*Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan*
- P-043** Clinical efficacy of 131I-MIBG therapy in 105 patients with pheochromocytomas/paragangliomas in China  
**Yu-Jun Shao**  
*Radionuclide Treatment Center, Beijing 401 Hospital of Chinese Nuclear Industry, Beijing, China*
- P-044** Biokinetics of radiolabeled octreotide and MIBG in patients with metastatic pheochromocytoma and paragangliomas  
**Bo Wangberg**  
*Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden*

- P-045 High dose versus low dose I-131 MIBG therapy for malignant pheochromocytoma/paraganglioma**  
**Daniel A Pryma**  
*Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA, United States of America*
- P-046 Malignant nature unveiled, many Years after surgical Removal of retroperitoneal Paraganglioma**  
**Rieko Nakatani**  
*Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan*
- P-047 Inhibition of S6K1 is Sufficient for Induction of Apoptosis and Proliferation but not Autophagy in PC12 cells**  
**Kazuhiro Takekoshi**  
*Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan*
- P-048 Evaluation of the preoperative management of Japanese clinical guide to the management of pheochromocytoma 2012**  
**Shigeatsu Hashimoto**  
*Department of Nephrology, Hypertension, Diabetology, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan*
- P-049 Long term effects of surgical resection of pheochromocytoma or paraganglioma on body weight**  
**Heather Wachtel**  
*Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, United States of America*
- P-050 Whole body MRI screening effectively identifies occult tumors in unaffected SDHB mutations carriers**  
**Lauren Fishbein**  
*Department of Medicine, Division of Endocrinology, University of Pennsylvania, PA, United States of America*
- P-051 Succinate Dehydrogenase B (SDHB) related bladder paragangliomas**  
**Umasuthan Srirangalingam**  
*Endocrinology, St Bartholomew's Hospital, Kent, United Kingdom*
- P-052 Clinical and genetic features of Chinese von Hippel-Lindau families with pheochromocytoma**  
**An-li Tong**  
*Endocrinology, Peking Union Medical College Hospital, Beijing, China*
- P-053 Extending disease phenotypes in the SDHA associated familial paraganglioma syndromes**  
**Umasuthan Srirangalingam**  
*Endocrinology, St Bartholomew's Hospital, Kent, United Kingdom*
- P-054 Pheochromocytoma/paraganglioma syndrome in patients with neurofibromatosis type 1: Case series of 15 patients**  
**Irina Bancos**  
*Endocrinology, Mayo Clinic, Rochester, MN, United States of America*
- P-055 SDHB surveillance regimen - a single UK institution experience**  
**Umasuthan Srirangalingam**  
*Endocrinology, St Bartholomew's Hospital, Kent, United Kingdom*